Evidence map›Paper›PMID 38960687›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Repeated Intravenous Methylprednisolone May Prevent Deterioration of Hypertrophic Pachymeningitis in Rosai-Dorfman Disease.

Toshiki Tezuka, Tomonori Nukariya, Nobuyuki Takahashi, Kenji Kufukihara, Naoko Tsuyama, Yasuhito Terui, Kaori Kameyama, Jin Nakahara, Tsubasa Takizawa

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Toshiki TezukaDepartment of Neurology, Keio University School of Medicine, Japan.
Tomonori NukariyaDepartment of Neurology, Keio University School of Medicine, Japan.
Nobuyuki TakahashiDepartment of Neurology, Keio University School of Medicine, Japan.
Kenji KufukiharaDepartment of Neurology, Keio University School of Medicine, Japan.
Naoko TsuyamaDivision of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Japan.
Yasuhito TeruiDepartment of Hematology and Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan.
Kaori KameyamaDepartment of Pathology, Keio University School of Medicine, Japan.
Jin NakaharaDepartment of Neurology, Keio University School of Medicine, Japan.
Tsubasa TakizawaDepartment of Neurology, Keio University School of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rosai-Dorfman disease (RDD) is a rare form of non-Langerhans cell histiocytosis. Although 20% of patients with RDD have spontaneous remission, some cases with central nervous system (CNS) involvement require surgery or systemic treatment. We encountered a case of RDD in which hypertrophic pachymeningitis was diffuse, eliminating the need for surgical intervention. A 72-year-old Japanese man was diagnosed with RDD based on pathological lymph node findings. Repeated intravenous methylprednisolone (IVMP) administration resolved and stabilized the hypertrophic pachymeningitis without any sequelae. If surgery or anticancer medications are contraindicated, repeated IVMP may be a good therapeutic option for CNS-associated RDD.

Indexed as

Histiocytosis, SinusMeningitisMethylprednisoloneAdministration, IntravenousAgedHumansHypertrophyMaleMethylprednisoloneemperipolesishypertrophic pachymeningitisintravenous methylprednisoloneRosai-Dorfman disease

Identifiers

PMID38960687
PMCPMC11867744

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.